CLINICAL TRIALS PROFILE FOR CETIRIZINE HYDROCHLORIDE HIVES RELIEF

505(b)(2) Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES RELIEF

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT02024152 ↗	Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg	Completed	Algorithme Pharma Inc	Phase 1	2011-03-01	This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
OTC	NCT02024152 ↗	Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg	Completed	JDP Therapeutics, Inc.	Phase 1	2011-03-01	This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.
OTC	NCT02865018 ↗	Neuromyelitis Optica (NMO) & Cetirizine	Completed	Guthy Jackson Charitable Foundation	Phase 1/Phase 2	2014-04-01	Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability. Without treatment, within 5 years 50% of NMO patients are blind in one or both eyes or require walking assistance (cane, walker or wheelchair). NMO has only been relatively recently described and is fairly rare. Most NMO patients' immune systems produce abnormal antibodies against aquaporin-4 (AQP4), which is found in certain cells in the central nervous system. When these AQP4 antibodies bind to AQP4, they trigger a cascade of events involving the immune system which eventually leads to damage to the nervous system. This ultimately leads to disability, some of which is permanent. Until now, treatments for NMO have been mostly focused on decreasing production of this AQP4 antibody. However, recent experiments in animal models of NMO have shown the importance of what happens inside the central nervous system after the antibody binds to the nervous system cell. Specifically, researchers have noted the importance of a specific cell type, eosinophils, in causing damage in NMO lesions. In a recent study, researchers showed they could prevent damage from NMO by blocking eosinophils using cetirizine, which is a popular over-the-counter allergy medicine. Cetirizine is already known to be safe and well-tolerated in the general population. In this study, the researchers plan to add cetirizine on to patients' current NMO treatment. The researchers aim to show that it is safe, well-tolerated, and that with cetirizine, NMO patients have less relapses and therefore less disability over the course of the year following initiation of treatment. The researchers also plan to study how cetirizine changes the immunological profile in NMO patients by examining blood and cerebrospinal fluid.
OTC	NCT02865018 ↗	Neuromyelitis Optica (NMO) & Cetirizine	Completed	Guthy Jackson Foundation	Phase 1/Phase 2	2014-04-01	Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability. Without treatment, within 5 years 50% of NMO patients are blind in one or both eyes or require walking assistance (cane, walker or wheelchair). NMO has only been relatively recently described and is fairly rare. Most NMO patients' immune systems produce abnormal antibodies against aquaporin-4 (AQP4), which is found in certain cells in the central nervous system. When these AQP4 antibodies bind to AQP4, they trigger a cascade of events involving the immune system which eventually leads to damage to the nervous system. This ultimately leads to disability, some of which is permanent. Until now, treatments for NMO have been mostly focused on decreasing production of this AQP4 antibody. However, recent experiments in animal models of NMO have shown the importance of what happens inside the central nervous system after the antibody binds to the nervous system cell. Specifically, researchers have noted the importance of a specific cell type, eosinophils, in causing damage in NMO lesions. In a recent study, researchers showed they could prevent damage from NMO by blocking eosinophils using cetirizine, which is a popular over-the-counter allergy medicine. Cetirizine is already known to be safe and well-tolerated in the general population. In this study, the researchers plan to add cetirizine on to patients' current NMO treatment. The researchers aim to show that it is safe, well-tolerated, and that with cetirizine, NMO patients have less relapses and therefore less disability over the course of the year following initiation of treatment. The researchers also plan to study how cetirizine changes the immunological profile in NMO patients by examining blood and cerebrospinal fluid.
OTC	NCT02865018 ↗	Neuromyelitis Optica (NMO) & Cetirizine	Completed	Icahn School of Medicine at Mount Sinai	Phase 1/Phase 2	2014-04-01	Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability. Without treatment, within 5 years 50% of NMO patients are blind in one or both eyes or require walking assistance (cane, walker or wheelchair). NMO has only been relatively recently described and is fairly rare. Most NMO patients' immune systems produce abnormal antibodies against aquaporin-4 (AQP4), which is found in certain cells in the central nervous system. When these AQP4 antibodies bind to AQP4, they trigger a cascade of events involving the immune system which eventually leads to damage to the nervous system. This ultimately leads to disability, some of which is permanent. Until now, treatments for NMO have been mostly focused on decreasing production of this AQP4 antibody. However, recent experiments in animal models of NMO have shown the importance of what happens inside the central nervous system after the antibody binds to the nervous system cell. Specifically, researchers have noted the importance of a specific cell type, eosinophils, in causing damage in NMO lesions. In a recent study, researchers showed they could prevent damage from NMO by blocking eosinophils using cetirizine, which is a popular over-the-counter allergy medicine. Cetirizine is already known to be safe and well-tolerated in the general population. In this study, the researchers plan to add cetirizine on to patients' current NMO treatment. The researchers aim to show that it is safe, well-tolerated, and that with cetirizine, NMO patients have less relapses and therefore less disability over the course of the year following initiation of treatment. The researchers also plan to study how cetirizine changes the immunological profile in NMO patients by examining blood and cerebrospinal fluid.

All Clinical Trials for CETIRIZINE HYDROCHLORIDE HIVES RELIEF

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00150761 ↗	Facial Thermography Study of Levocetirizine Versus Cetirizine	Completed	UCB Pharma	Phase 4	2004-07-01	Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods) cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine and cetirizine by means of IR thermography.
NCT00189397 ↗	Azathioprine Versus Corticosteroids in Parthenium Dermatitis	Completed	All India Institute of Medical Sciences, New Delhi	N/A	2003-02-01	The dermatitis caused by the substances which come in contact with the skin is known as contact dermatitis. When such a reaction is caused by the agents suspended in the air, it is called air-borne contact dermatitis (ABCD). Parthenium hysterophorus at present is the commonest cause of ABCD in India though in some cases other plants have also been found to cause ABCD. Parthenium dermatitis is one of the major health problems in dermatology in our country. Though it has very little mortality, the disease normally continues to persist with variable remissions and relapses causing great distress and morbidity. Corticosteroids, topical and systemic have been the mainstay of the treatment so far. Therefore, the patients with ABCD who have to take corticosteroids for long periods of time tend to develop severe and sometimes irreversible side effects of the therapy. Azathioprine is an immunosuppressive drug which acts by inhibiting the T lymphocytes. In our previous studies we have been able to induce remissions in these patients with azathioprine used as daily as well as monthly bolus dose, without having to use systemic corticosteroids. The side effect with azathioprine in these studies were almost absent. We have therefore planned to study the therapeutic efficacy of azathioprine weekly pulse doses versus daily azathioprine in achieving remissions in patients having Parthenium dermatitis and to monitor the side effects of both the regimens.
NCT00253058 ↗	Study Of Perennial Allergic Rhinitis In Pediatrics	Completed	GlaxoSmithKline	Phase 3	2005-07-01	To verify of cetirizine dry syrup to ketotifen dry syrup in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period
NCT00257569 ↗	Study Of Atopic Dermatitis In Pediatrics	Completed	GlaxoSmithKline	Phase 3	2005-08-01	To verify of cetirizine dry syrup to ketotifen dry syrup in the change in the severity of pruritus of the treatment period.
NCT00257582 ↗	Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics	Completed	GlaxoSmithKline	Phase 3	2005-08-01	To assess the safety of long-term use of cetirizine dry syrup in children with various type of cutaneous disease accompanied on pruritus.
NCT00257595 ↗	Perennial Allergic Rhinitis In Pediatric Subjects	Completed	GlaxoSmithKline	Phase 3	2005-08-01	To assess the safety of long-term use of cetirizine dry syrup in children with perennial allergic rhinitis.
NCT00291642 ↗	A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen	Completed	UCB Pharma	Phase 2	2006-01-01	The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in ragweed sensitive adult subjects exposed to ragweed pollen in an Environmental Exposure Unit.

Clinical Trial Conditions for CETIRIZINE HYDROCHLORIDE HIVES RELIEF

Condition Name

Condition Name for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Intervention	Trials
Allergic Rhinitis	11
Seasonal Allergic Rhinitis	9
Healthy	9
Urticaria	6

Condition MeSH

Condition MeSH for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Intervention	Trials
Rhinitis, Allergic	34
Rhinitis	34
Rhinitis, Allergic, Seasonal	15
Urticaria	12

Clinical Trial Locations for CETIRIZINE HYDROCHLORIDE HIVES RELIEF

Trials by Country

Trials by Country for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Location	Trials
United States	56
Canada	13
Germany	5
Italy	3
Egypt	3

Trials by US State

Trials by US State for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Location	Trials
Texas	9
Massachusetts	4
Maryland	4
New York	3
Pennsylvania	3

Clinical Trial Progress for CETIRIZINE HYDROCHLORIDE HIVES RELIEF

Clinical Trial Phase

Clinical Trial Phase for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Clinical Trial Phase	Trials
PHASE3	2
Phase 4	24
Phase 3	21

Clinical Trial Status

Clinical Trial Status for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Clinical Trial Phase	Trials
Completed	70
Recruiting	12
Unknown status	4

Clinical Trial Sponsors for CETIRIZINE HYDROCHLORIDE HIVES RELIEF

Sponsor Name

Sponsor Name for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Sponsor	Trials
GlaxoSmithKline	12
UCB Pharma	6
Merck Sharp & Dohme Corp.	5

Sponsor Type

Sponsor Type for CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Sponsor	Trials
Industry	70
Other	51
NIH	2

CETIRIZINE HYDROCHLORIDE HIVES RELIEF Market Analysis and Financial Projection

Last updated: April 28, 2026

Cetirizine Hydrochloride (Hives Relief): Clinical Trial Update, Market Readout, and Pricing-Linked Projections

Where does cetirizine hydrochloride sit in clinical development for hives (chronic urticaria/urticaria)?

Cetirizine hydrochloride is an established second-generation H1 antihistamine used for urticaria and chronic spontaneous urticaria (CSU). The development program is mature: most evidence comes from historical Phase 3 activity plus ongoing incremental studies focused on comparative efficacy, special populations, and formulation.

Clinical evidence base (high-level)

• Indication scope: urticaria, including chronic spontaneous urticaria and acute urticaria in many jurisdictions.
• Mechanism: selective peripheral H1 receptor antagonism; reduces histamine-driven pruritus and wheal formation.
• Clinical pattern: trials typically compare cetirizine (often 10 mg once daily) versus other antihistamines, placebo, or add-on regimens; endpoints commonly include itch (pruritus) score and number/size of wheals.

Regulatory status and label anchoring (what matters for market access)

• Cetirizine is widely marketed globally as an OTC or prescription product depending on country.
• Labeling for urticaria uses standard dosing (commonly 10 mg once daily in adults; pediatric dosing by weight/age in many labels).

Practical consequence for “clinical trials update”

• For investment-grade timing, “new cetirizine for hives” development is generally not a clean path to new market exclusivity. The clinical base is already sufficient for generic and branded line extensions, which shifts value creation toward:
  • formulation differentiation (liquid, melt, extended-release, pediatric-friendly presentations)
  • delivery convenience (once-daily, fast-acting variants where supported by data)
  • label expansion (limited; often bounded by existing guidance and payer behavior)

Key analytical point: in a mature antihistamine category, the “clinical update” that changes commercialization outcomes is typically not efficacy discovery; it is the ability to secure payer coverage and shelf conversion via differentiated dosing forms and health-economics arguments.

What does the market look like for cetirizine in hives relief, and where is demand concentrated?

Cetirizine is part of the global oral antihistamine market for allergic rhinitis and urticaria. Hives relief is a smaller, but recurring, driver within urticaria-managed spend, with demand influenced by seasonality (for acute urticaria presentations) and by chronicity-driven behavior (for CSU).

Market demand drivers

• Chronic spontaneous urticaria (CSU): long-duration symptom management supports repeat purchasing, but treatment pathways often escalate beyond oral antihistamines for refractory CSU.
• Switching and brand pressure: once a patient is controlled on a second-generation antihistamine, the typical commercial outcome is brand-to-generic switching, especially where payers apply step edits or low copays favor generics.
• Pediatric access: liquid and age-appropriate formulations expand addressable use.

Channel economics (where the money moves)

In most geographies, antihistamine volumes move through:

• OTC pharmacy retail for mild to intermittent urticaria/itch management
• generic prescription channels where payer copays and formulary tiers compress branded differentiation

Actionable implication: the “market analysis and projection” for cetirizine hives relief depends more on competitive pricing and package strategy than on clinical innovation.

How should projections be built for cetirizine hives relief given generic competition?

A robust projection must be pricing-linked and share-aware: cetirizine’s market is structurally pressured by generic entry. That makes topline growth track:

• total unit growth (population, diagnosis awareness, pediatric use)
• substitution dynamics (brand vs generic share)
• price erosion (especially after generic clustering in key markets)

Projection framework (used for decisioning, not forecasts in isolation)

Revenue = Units × Net Price. For cetirizine:

• Units grow slowly in mature markets, with periodic lifts from pack size changes, seasonal peaks, and promotional cycles.
• Net price erodes continuously due to generic competition and pharmacy reimbursement patterns.
• Formula for earnings durability shifts to:
  • manufacturing cost control
  • packaging optimization (small packs for OTC; larger packs for retail value corridors)
  • differentiation that reduces pure price elasticity (taste, dosing ease, pediatric acceptability)

Hives-relief-specific demand assumption

Urticaria is often treated by:

• starting with a second-generation antihistamine at standard dose
• escalating dose for CSU in practice (where guideline-based practice allows dose up-titration under clinician supervision)
• moving to add-ons (dose escalation, omalizumab, cyclosporine) in refractory cases

This means cetirizine’s “hives relief” share is highest in:

• early line management
• mild CSU and cases responding to antihistamine class treatment
• settings where cost containment favors inexpensive oral therapy

Commercial outlook (directional)

• Base case: stable-to-modest unit growth with continued price compression, leading to low single-digit revenue growth in mature markets and more variable outcomes in emerging markets (more OTC penetration and diagnosis awareness).
• Upside case: differentiated pediatric and convenience formats that raise effective net price and reduce switching.
• Downside case: aggressive generic price competition and formulary tightening in prescription markets.

What are the patent and exclusivity realities for cetirizine that shape investment returns?

Cetirizine hydrochloride is an old active ingredient. For hives relief, the meaningful intellectual property landscape is usually:

• expired composition-of-matter (typical for established APIs)
• formulation and method-of-use niches (limited, often not broad enough for long commercial protection across markets)
• brand lifecycle: revenue depends on market access strategy, not exclusivity

Implication for “clinical trials update”: the main credible route to incremental value is not new Phase 3 development for an already-established indication. It is defensible product differentiation and procurement competitiveness.

Where are the highest-probability R&D moves if the goal is hives relief commercialization?

Given cetirizine’s maturity, high-probability development themes are constrained to what changes buying behavior:

• Pediatric-friendly presentations: syrups, drops, orally dissolving formats that improve adherence and caregiver acceptance.
• Onset and dosing convenience claims: fast-onset formulations where supported by clinical pharmacology or appropriately designed clinical endpoints.
• Combination products: only where local regulations and payer acceptability support additional value; otherwise, it increases regulatory and reimbursement complexity.
• Comparative effectiveness studies: primarily to support switching and formulary positioning, not to replace first-line guidance.

What signals matter to track next for clinical and commercial read-through?

For cetirizine in hives relief, the decision-grade signals are:

Clinical signal set

• Evidence for pruritus control and wheal reduction in CSU cohorts under real-world dosing practices.
• Safety outcomes relevant to long-term use (sedation profiles, pediatric tolerability).
• Compliance endpoints tied to formulation differences (taste, administration ease).

Commercial signal set

• Retail shelf price movements for 10 mg tablets and liquid formulations.
• Generic entry intensity by country and distributor.
• OTC vs Rx channel share for urticaria-itch use.

How does this translate into market projection scenarios?

Scenario matrix for “hives relief” revenue (directional)

Scenario	Drivers	Revenue Direction
Base case	Slow unit growth, continued price compression	Flat to low single-digit growth
Upside	Differentiated pediatric formats raise net price; improved pack conversion	Low single-digit to mid single-digit growth
Downside	More aggressive price competition; OTC promotions compress margins	Flat to decline

Decision thresholds (commercial)

• If net price erosion accelerates faster than unit growth, revenue declines even with stable demand.
• Differentiation only pays if it lifts net price or reduces promo dependence enough to offset higher COGS and marketing.

What should investors and R&D teams conclude for cetirizine hives relief?

Cetirizine hydrochloride is a mature, widely accessible therapy for urticaria and CSU. The “clinical update” is mostly a continuation of evidence refinement and comparative positioning. The market path is dominated by generic economics, channel strategy, and product-format differentiation rather than new therapeutic breakthroughs.

Key Takeaways

• Cetirizine is an established second-generation H1 antihistamine for urticaria/CSU with a mature clinical evidence base, making new Phase 3 efficacy programs a weak exclusivity route.
• Commercial outcomes for hives relief hinge on generic competition, net price erosion, and formulation-driven shelf conversion, especially for pediatric use.
• Projections should be built on Units × Net Price with scenarios that explicitly model continued price pressure and modest volume growth.
• The highest-probability incremental R&D value sits in pediatric-friendly and convenience-focused formulations that can hold net price better or increase adherence-driven repeat purchasing.

FAQs

1. Is cetirizine still the standard first-line option for hives (CSU/urticaria)?
   Yes in clinical practice and product labeling across many markets as an initial oral antihistamine step.

2. What drives revenue for cetirizine hives relief in mature markets?
   Net price and channel mix (OTC vs Rx), plus package and formulation strategy that influences conversion and adherence.

3. Do new clinical trials for cetirizine typically create market exclusivity?
   Rarely. For an established API, most new clinical activity supports positioning rather than creating durable exclusivity.

4. How should dose escalation be treated in market modeling?
   It can increase units per controlled patient in CSU, but reimbursement and clinical pathway effects determine how much of that utilization accrues to cetirizine versus alternative therapies.

5. What product formats matter most for pediatric urticaria management?
   Liquid and easy-to-administer options that improve caregiver acceptance and adherence.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Cetirizine hydrochloride prescribing information/labeling. FDA. https://www.fda.gov
[2] European Medicines Agency. (n.d.). Assessment reports and product information for cetirizine-containing medicines. EMA. https://www.ema.europa.eu
[3] National Library of Medicine. (n.d.). ClinicalTrials.gov: cetirizine urticaria/chronic spontaneous urticaria search results. ClinicalTrials.gov. https://clinicaltrials.gov
[4] American Academy of Allergy, Asthma & Immunology. (n.d.). Urticaria/CSU treatment guidance and antihistamine-based step therapy overview. AAAAI. https://www.aaaai.org
[5] EAACI (European Academy of Allergy and Clinical Immunology). (n.d.). Guidance on chronic spontaneous urticaria management and antihistamine use. EAACI. https://www.eaaci.org